Literature DB >> 28786124

Risk factors for metastatic prostate cancer: A sentinel event case series.

Channing J Paller1, Alexander P Cole2, Alan W Partin3, Michael A Carducci1, Norma F Kanarek4,5.   

Abstract

BACKGROUND: Root cause analysis is a technique used to assess systems factors related to "sentinel events"-serious adverse events within healthcare systems. This technique is commonly used to identify factors, which allowed these adverse events to occur, to target areas for improvement and to improve health care delivery systems. We sought to apply this technique to men presenting with metastatic prostate cancer (PCa).
METHODS: We performed an in-depth case series analysis of 15 patients, who presented with metastatic disease at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center using root cause analysis to refine a list of health system factors that lead to late stage presentation in the current era.
RESULTS: Key factors in late diagnosis of PCa included lack of insurance, lack of routine PSA testing, comorbidities, reticence of patients to follow up actionable PSA, and aggressive disease. Three patients had aggressive disease that would not have been discovered at an early stage in the disease process, despite routine screening. However, analysis of the remaining 12 patients illuminated health system factors led to missing important diagnostic information, which might have led to diagnosis of PCa at a curable stage.
CONCLUSIONS: The cases help highlight the need for systems based approaches to early diagnosis of PCa. A heterogeneous group of barriers to early diagnosis were identified in our series of patients including economic, health systems, and cultural factors. These findings underscore the need for individualized approaches to preventing delayed diagnosis of PCa. While limited by our single-institution scope, this approach provides a model for research and quality improvement initiatives to identify modifiable systems factors impeding appropriate diagnoses of PCa.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  PSA screening; case series; health services research; metastatic prostate cancer; risk factors; root-cause analysis; sentinel events

Mesh:

Substances:

Year:  2017        PMID: 28786124      PMCID: PMC5621513          DOI: 10.1002/pros.23396

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

2.  Patient Function and the Value of Surgical Care for Kidney Cancer.

Authors:  Hung-Jui Tan; Joseph D Shirk; Karim Chamie; Mark S Litwin; Jim C Hu
Journal:  J Urol       Date:  2016-12-13       Impact factor: 7.450

3.  Prostate cancer screening between low-income African-American and Caucasian men.

Authors:  Jay H Fowke; David Schlundt; Lisa B Signorello; Flora A M Ukoli; William J Blot
Journal:  Urol Oncol       Date:  2005 Sep-Oct       Impact factor: 3.498

4.  Understanding prostate cancer spending growth among Medicare beneficiaries.

Authors:  Yun Zhang; Ted A Skolarus; David C Miller; John T Wei; Brent K Hollenbeck
Journal:  Urology       Date:  2010-12-18       Impact factor: 2.649

Review 5.  Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

Authors:  Channing J Paller; Emmanuel S Antonarakis
Journal:  Hum Vaccin Immunother       Date:  2012-04-01       Impact factor: 3.452

6.  Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Georges Adunlin; Askal Ayalew Ali; Clement K Gwede; Youjie Huang
Journal:  Am J Mens Health       Date:  2014-12-26

Review 7.  Adverse effects of androgen deprivation therapy and strategies to mitigate them.

Authors:  Paul L Nguyen; Shabbir M H Alibhai; Shehzad Basaria; Anthony V D'Amico; Philip W Kantoff; Nancy L Keating; David F Penson; Derek J Rosario; Bertrand Tombal; Matthew R Smith
Journal:  Eur Urol       Date:  2014-08-02       Impact factor: 20.096

8.  Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.

Authors:  Jesse D Sammon; Deepansh Dalela; Firas Abdollah; Toni K Choueiri; Paul K Han; Moritz Hansen; Paul L Nguyen; Akshay Sood; Mani Menon; Quoc-Dien Trinh
Journal:  J Urol       Date:  2015-11-17       Impact factor: 7.450

9.  Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.

Authors:  Ryan Hutchinson; Abdulhadi Akhtar; Justin Haridas; Deepa Bhat; Claus Roehrborn; Yair Lotan
Journal:  Cancer       Date:  2016-09-22       Impact factor: 6.860

10.  Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers.

Authors:  U Macleod; E D Mitchell; C Burgess; S Macdonald; A J Ramirez
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

View more
  1 in total

1.  Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Authors:  Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng
Journal:  JCO Precis Oncol       Date:  2018-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.